Protease Inhibitor Therapeutics for Respiratory Disease By Dr Philip J. Barr Disruption of the natural equilibria between proteases and their cognate inhibitors is a common feature of inflammatory disease. When this occurs in the lung, the effects can lead to irreversible impairment of pulmonary function. Although protease inhibition has been standard therapy for hereditary emphysema […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!